Oscar Health (OSCR) Stock Forecast & Price Target

Compare

2,401 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

OSCR Analyst Ratings

Hold

1 Buy

3 Hold

2 Sell

Based on 6 analysts giving stock ratings to

Oscar

Health

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

OSCR Stock 12 Month Forecast

Average Price Target

$16.67

▼(-0.12% Downside)

Based on 6 Wall Street analysts offering 12 month price targets for Oscar Health in the last 3 months. The average price target is $16.67 with a high forecast of $25.00 and a low forecast of $11.00. The average price target represents a -0.12% change from the last price of $16.69.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"10":"$10","14":"$14","18":"$18","22":"$22","26":"$26"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$25.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$16.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$11.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[10,14,18,22,26],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.37,15.187692307692307,16.005384615384614,16.823076923076922,17.64076923076923,18.45846153846154,19.276153846153846,20.09384615384615,20.911538461538463,21.729230769230767,22.54692307692308,23.364615384615384,24.182307692307692,{"y":25,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.37,14.546923076923076,14.723846153846154,14.90076923076923,15.077692307692308,15.254615384615384,15.431538461538462,15.608461538461539,15.785384615384617,15.962307692307693,16.13923076923077,16.31615384615385,16.493076923076924,{"y":16.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.37,14.11076923076923,13.85153846153846,13.592307692307692,13.333076923076923,13.073846153846153,12.814615384615385,12.555384615384614,12.296153846153846,12.036923076923078,11.777692307692307,11.518461538461539,11.259230769230768,{"y":11,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":13.44,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.6,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.61,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.97,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.05,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.26,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.45,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.58,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":16.43,"date":1756684800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 13</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":18.9,"date":1759276800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":18,"date":1761955200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 35, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":16.65,"date":1764547200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 45, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":14.37,"date":1767225600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 34, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$25.00

Average Price Target$16.67

Lowest Price Target$11.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Jonathan Yong

UBS

$12→$17

Hold

1.86%

Upside

Upgraded

01/09/26

Oscar Health: Improved Fundamentals and Earnings Outlook Largely Reflected in Fair Valuation, Supporting Neutral/Hold Rating

Andrew Mok CFA

Barclays

$13→$18

Hold

7.85%

Upside

Upgraded

01/05/26

Oscar Health upgraded to Equal Weight from Underweight at BarclaysOscar Health upgraded to Equal Weight from Underweight at Barclays

David Windley

Jefferies

$12

Sell

-28.10%

Downside

Reiterated

12/22/25

Oscar faces elevated SEP-driven MLR risk in Georgia, says JefferiesOscar faces elevated SEP-driven MLR risk in Georgia, says Jefferies

Raj Kumar CFA

Stephens

$17

Hold

1.86%

Upside

Initiated

12/11/25

Oscar Health: Navigating Growth Opportunities Amidst Underwriting Volatility and Policy Uncertainty

Jessica Tassan

Piper Sandler

$13→$25

Buy

49.79%

Upside

Upgraded

11/26/25

Oscar Health upgraded to Overweight from Neutral at Piper SandlerOscar Health upgraded to Overweight from Neutral at Piper Sandler

Stephen Baxter

Wells Fargo

$14→$11

Sell

-34.09%

Downside

Reiterated

11/13/25

Cautious Outlook on Oscar Health: Sell Rating Amid Uncertain Profitability and Market Dynamics

Scott Fidel

Goldman Sachs

$19.29

Hold

15.58%

Upside

Initiated

10/14/25

Oscar Health (OSCR) Has a New Rating from Goldman Sachs

Michael Ha

Robert W. Baird

Hold

―

Reiterated

08/14/25

Robert W. Baird Keeps Their Hold Rating on Oscar Health (OSCR)

Joanna Gajuk

Bank of America Securities

$11

Sell

-34.09%

Downside

Reiterated

08/06/25

Cautious Outlook: Oscar Health's Financial Challenges and Sell Recommendation Amid Industry Uncertainties

John Ransom

Raymond James

Hold

―

Downgraded

06/24/25

Oscar Health downgraded to Market Perform from Outperform at Raymond JamesOscar Health downgraded to Market Perform from Outperform at Raymond James

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Jonathan Yong

UBS

$12→$17

Hold

1.86%

Upside

Upgraded

01/09/26

Oscar Health: Improved Fundamentals and Earnings Outlook Largely Reflected in Fair Valuation, Supporting Neutral/Hold Rating

Andrew Mok CFA

Barclays

$13→$18

Hold

7.85%

Upside

Upgraded

01/05/26

Oscar Health upgraded to Equal Weight from Underweight at BarclaysOscar Health upgraded to Equal Weight from Underweight at Barclays

David Windley

Jefferies

$12

Sell

-28.10%

Downside

Reiterated

12/22/25

Oscar faces elevated SEP-driven MLR risk in Georgia, says JefferiesOscar faces elevated SEP-driven MLR risk in Georgia, says Jefferies

Raj Kumar CFA

Stephens

$17

Hold

1.86%

Upside

Initiated

12/11/25

Oscar Health: Navigating Growth Opportunities Amidst Underwriting Volatility and Policy Uncertainty

Jessica Tassan

Piper Sandler

$13→$25

Buy

49.79%

Upside

Upgraded

11/26/25

Oscar Health upgraded to Overweight from Neutral at Piper SandlerOscar Health upgraded to Overweight from Neutral at Piper Sandler

Stephen Baxter

Wells Fargo

$14→$11

Sell

-34.09%

Downside

Reiterated

11/13/25

Cautious Outlook on Oscar Health: Sell Rating Amid Uncertain Profitability and Market Dynamics

Scott Fidel

Goldman Sachs

$19.29

Hold

15.58%

Upside

Initiated

10/14/25

Oscar Health (OSCR) Has a New Rating from Goldman Sachs

Michael Ha

Robert W. Baird

Hold

―

Reiterated

08/14/25

Robert W. Baird Keeps Their Hold Rating on Oscar Health (OSCR)

Joanna Gajuk

Bank of America Securities

$11

Sell

-34.09%

Downside

Reiterated

08/06/25

Cautious Outlook: Oscar Health's Financial Challenges and Sell Recommendation Amid Industry Uncertainties

John Ransom

Raymond James

Hold

―

Downgraded

06/24/25

Oscar Health downgraded to Market Perform from Outperform at Raymond JamesOscar Health downgraded to Market Perform from Outperform at Raymond James

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Oscar Health

3 Months

xxx

Success Rate

7/20 ratings generated profit

Average Return

+2.18%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 35.00% of your transactions generating a profit, with an average return of +2.18% per trade.

1 Year

Stephen BaxterWells Fargo

Success Rate

8/20 ratings generated profit

Average Return

+36.45%

reiterated a sell rating 2 months ago

Copying Stephen Baxter's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of +36.45% per trade.

2 Years

xxx

Success Rate

8/20 ratings generated profit

Average Return

+28.54%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 40.00% of your transactions generating a profit, with an average return of +28.54% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

OSCR Analyst Recommendation Trends

Rating

Sep 25

Oct 25

Nov 25

Dec 25

Jan 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, OSCR has received 1 Buy Ratings, 34 Hold Ratings, and 7 Sell Ratings. OSCR average Analyst price target in the past 3 months is 16.67.

Each month's total comprises the sum of three months' worth of ratings.

OSCR Financial Forecast

OSCR Earnings Forecast

Next quarter’s earnings estimate for OSCR is -$0.90 with a range of -$1.07 to -$0.74. The previous quarter’s EPS was -$0.53. OSCR beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year OSCR has Performed in-line its overall industry.

OSCR Sales Forecast

Next quarter’s sales forecast for OSCR is $3.11B with a range of $3.04B to $3.15B. The previous quarter’s sales results were $2.99B. OSCR beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year OSCR has Performed in-line its overall industry.

OSCR Stock Forecast FAQ

What is OSCR’s average 12-month price target, according to analysts?

Based on analyst ratings, Oscar Health’s 12-month average price target is 16.67.

What is OSCR’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for OSCR, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is OSCR a Buy, Sell or Hold?

Oscar Health has a consensus rating of Hold which is based on 1 buy ratings, 3 hold ratings and 2 sell ratings.

What is Oscar Health’s price target?

The average price target for Oscar Health is 16.67. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $25.00 ,the lowest forecast is $11.00. The average price target represents -0.12% Decrease from the current price of $16.69.

What do analysts say about Oscar Health?

Oscar Health’s analyst rating consensus is a Hold. This is based on the ratings of 6 Wall Streets Analysts.

How can I buy shares of OSCR?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Oscar Health (OSCR) Stock Forecast & Price Target

OSCR Analyst Ratings

OSCR Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Oscar Health

OSCR Analyst Recommendation Trends

OSCR Financial Forecast

OSCR Earnings Forecast

OSCR Sales Forecast

OSCR Stock Forecast FAQ

Detailed List of Analyst Forecasts